IP Library Granted Patent US 8,420,806
Granted Patent B2
US 8,420,806 · App. 12/300,046 · Granted Apr 16, 2013

Process for the crystallisation of cefadroxil monohydrate

Inventors: Carlos Enrique Lenhard (Alella Barcelona, ES); Harold Monro Moody (Gulpen, NL); Theodorus Johannes Godfried Maria Van Dooren (Roermond, NL)
Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,806
App. No.
12/300,046
Granted
Apr 16, 2013
Kind
B2
Abstract

The present invention relates to a process for the preparation of cefadroxil in crystal form, comprising a) adding an aqueous solution of cefadroxil to a crystallization vessel and a titrant to keep a pH in the crystallization vessel of between 7 to 9; and b) lowering the pH in the crystallization vessel to a value of between 5 and 6.5 to obtain a suspension of the β-lactam compound in crystal form. The invention further relates to cefadroxil in crystal form obtainable by the process according to the present invention. The invention also relates to cefadroxil in crystal form with a CIE b value of below 12 when stored at a temperature of 25° C. for at least 1 month.

Claims (7)

1. A process for the preparation of cefadroxil monohydrate in crystal form, comprising:

a) bringing an aqueous solution of cefadroxil monohydrate to a pH of between 7 to 9 with a suitable titrant;

b) lowering the pH to a value of between 5 and 6.5 to obtain a suspension of cefadroxil monohydrate in crystal form; and

c) isolating the cefadroxil monohydrate in crystal form from the suspension obtained in step b).

2. The process according to claim 1 , wherein step a) and step b) are carried out at a temperature of between 5 and 25° C.

3. The process according to claim 1 , wherein lowering the pH in step b) is carried out within a period of time of between 20 to 60 min.

4. The process according to claim 1 , wherein the suspension of the cefadroxil monohydrate in crystal form obtained in step b) is stirred for 10 to 120 min.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2012
From: DSM IP ASSETS B.V.
To: DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.
Reel/Frame 028638/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2009
From: LENHARDT, CARLOS ENRIQUE; MOODY, HAROLD MONRO; VAN DOOREN, THEODORUS J.G.M.
To: DSM IP ASSETS B.V.
Reel/Frame 022710/0482 →
Priority Claims (1)
EP 06114240 · May 19, 2006 · regional
Continuity (1)
Related Publication 20100010213A1 · Jan 14, 2010